Basel, Switzerland
Basel, Switzerland

Time filter

Source Type

Notes:  Production, means the output of Buccal Drug Delivery Systems  Revenue, means the sales value of Buccal Drug Delivery Systems This report studies Buccal Drug Delivery Systems in Global Market, especially in North America, Europe, China, Japan, Southeast Asia and India, with production, revenue, consumption, import and export in these regions, from 2011 to 2015, and forecast to 2021. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering  Actavis  Angelini  Applied Pharma Research  Ardana Biosciences  Auxillium Pharma  Barr  Biodelivery Sciences  Blue fish  Cynapsus Pharma  Ethypharm By types, the market can be split into  Sublingual Films  Tablets  Sprays By Application, the market can be split into  Application 1  Application 2  Application 3 By Regions, this report covers (we can add the regions/countries as you want)  North America  China  Europe  Southeast Asia  Japan  India Global Buccal Drug Delivery Systems Market Professional Survey Report 2016  1 Industry Overview of Buccal Drug Delivery Systems  1.1 Definition and Specifications of Buccal Drug Delivery Systems  1.1.1 Definition of Buccal Drug Delivery Systems  1.1.2 Specifications of Buccal Drug Delivery Systems  1.2 Classification of Buccal Drug Delivery Systems  1.2.1 Sublingual Films  1.2.2 Tablets  1.2.3 Sprays  1.3 Applications of Buccal Drug Delivery Systems  1.3.1 Application 1  1.3.2 Application 2  1.3.3 Application 3  1.4 Market Segment by Regions  1.4.1 North America  1.4.2 China  1.4.3 Europe  1.4.4 Southeast Asia  1.4.5 Japan  1.4.6 India 2 Manufacturing Cost Structure Analysis of Buccal Drug Delivery Systems  2.1 Raw Material and Suppliers  2.2 Manufacturing Cost Structure Analysis of Buccal Drug Delivery Systems  2.3 Manufacturing Process Analysis of Buccal Drug Delivery Systems  2.4 Industry Chain Structure of Buccal Drug Delivery Systems 3 Technical Data and Manufacturing Plants Analysis of Buccal Drug Delivery Systems  3.1 Capacity and Commercial Production Date of Global Buccal Drug Delivery Systems Major Manufacturers in 2015  3.2 Manufacturing Plants Distribution of Global Buccal Drug Delivery Systems Major Manufacturers in 2015  3.3 R&D Status and Technology Source of Global Buccal Drug Delivery Systems Major Manufacturers in 2015  3.4 Raw Materials Sources Analysis of Global Buccal Drug Delivery Systems Major Manufacturers in 2015 4 Global Buccal Drug Delivery Systems Overall Market Overview  4.1 2011-2016E Overall Market Analysis  4.2 Capacity Analysis  4.2.1 2011-2016E Global Buccal Drug Delivery Systems Capacity and Growth Rate Analysis  4.2.2 2015 Buccal Drug Delivery Systems Capacity Analysis (Company Segment)  4.3 Sales Analysis  4.3.1 2011-2016E Global Buccal Drug Delivery Systems Sales and Growth Rate Analysis  4.3.2 2015 Buccal Drug Delivery Systems Sales Analysis (Company Segment)  4.4 Sales Price Analysis  4.4.1 2011-2016E Global Buccal Drug Delivery Systems Sales Price  4.4.2 2015 Buccal Drug Delivery Systems Sales Price Analysis (Company Segment) Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.


BUCCAL Drug Delivery Systems Market analysis is provided for global market including development trends by regions, competitive analysis of the BUCCAL Drug Delivery Systems market. BUCCAL Drug Delivery Systems Industry report focuses on the major drivers and restraints for the key players. “BUCCAL Drug Delivery Systems: Opportunities and Challenges in Buccal, Sublingual Films, Tablets & Sprays - Detailed Analysis on Technologies and Pipeline Development” report speaks about the manufacturing process. The process is analysed thoroughly with respect four points Manufacturers, regional analysis, Segment by Type and Segment by Applications and the actual process of whole BUCCAL Drug Delivery Systems industry. Within the oral mucosal cavity, the buccal region offers an attractive route of administration for systemic drug delivery. The mucosa has a rich blood supply and it is relatively permeable. The buccal mucosa offers several advantages for controlled drug delivery for extended periods of time. The mucosa is well supplied with both vascular and lymphatic drainage and first-pass metabolism in the liver and pre-systemic elimination in the gastrointestinal tract are avoided. The area is well suited for a retentive device and appears to be acceptable to the patient. With the right dosage form design and formulation, the permeability and the local environment of the mucosa can be controlled and manipulated in order to accommodate drug permeation. Buccal drug delivery is a promising area for continued research with the aim of systemic delivery of orally inefficient drugs as well as a feasible and attractive alternative for non-invasive delivery of potent peptide and protein drug molecules. In 2014, sales of Suboxone sublingual film totalled approximately $1.3 billion in the U.S. while the total market grew to more than $1.7 billion, driven by a 11 percent increase in prescriptions. In 2014, Bunavail buccal film has received US approval which has similar bioavailability of suboxone with half of the dose of buprenorphine. Global pharma companies such as Biodelivery Sciences, Bioalliance pharma (Onexo), Meda pharma, Orexo, Generex, Teijin are actively involved in developing oral mucoadhesive buccal delivery systems while sublingual technology have been used by Teva, Sun pharma, Grunenthal, Neurax, Angelini, Sandoz, Ethypharm, Arrow generics, Purdue and Actavis pharma. Sublingual spray technology have been employed by the companies such as Insys therapeutics, Perrigo, Mist pharm, Regency, Novadel, Generex, GW Pharma and Pohl Boskamp in developing potential drugs for the patients. Other than drugs used for local actions (antifungal, antiviral), generally controlled substances like buprenorphine, naloxone and fentanyl are preferred to release the drug through buccal formulations. However, testosterone (striant) to treat low testosterone levels in men also approved through use of buccal system of delivery. In the US, drugs such as Isosorbide dinitarte, ergoloid delivered sublingually have been discontinued and nitroglycerin has been replaced with sublingual metered spray. Ergomar (ergotamine tartarate) marketed by Rosedale therapeutics is the only sublingual tablets available in the US market, priced $15 per pill. Subsys (fentanyl) developed by Insys therapeutics was the recent sublingual spray approved in the US for the treatment of breakthrough cancer pain. Ease of administration and better compliance offered by delivering through buccal route offers advantages for patients and physicians over other Invasive route and oral ingestion will drive the market further in positive directions going forward. Novel buccal delivery such as soluble thin films, mucoadhesive films and rapidmist spray offers newer route of delivery for the generics that has lesser patients compliances. This report will provide detailed analysis on buccal delivery systems in broader pharma market in finding companies and technologies and complexities involved in developing this unique high potential delivery system. 6. Buccal Films • Formulation aspects • Ideal Characteristic of drugs/excipients for developing Buccal delivery formulations • Manufacturing Methods o Solvent casting method o Hot-melt extrusion o Semisolid casting o Solid dispersion o Rolling • Physico-Chemical Evaluation of Buccal Films • Marketed Buccal Films • Technologies used in Buccal/Sublingual films o BEMA o PharmaFilm 8. Sublingual films/Tablets Buccal/ sublingual formulations approved in the US including generics Buccal/ sublingual formulations discontinued in the US Buccal/ sublingual formulations underdevelopment worldwide Buccal /sublingual formulations approved in Europe 9. Other technologies used in buccal delivery systems • ArisGen Pharma (ArisCrown technology) • Mystic Pharma (VersiDoser powder technology) • Uluru (OraDisc Technology) • Tesa labtec (PerioPatch) – buccal patch • Intellidrug (Intraoral drug delivery device) • Generex Pharma (RapidMist Technology) • Insys therapeutics (sublingual spray) 10. Oral Thin fast Dissolving Films (OTF) –Ideal Characteristics, Classification and Evaluation • Auxillium Pharma (PharmForm Tech) • LTS Lohmann OTF • IntelGenx OTF • Tapemark Solustrip technology • Applied Pharma Research/Tesa Labtec – RapidFilm Technology • Tesa Labtec Pharma -Mucofilm • Cynapsus Pharma – Sublingual thin film • Seoul Pharma -SmartFilm • Other patented approaches o XGel film o Soluleaves o Wafertab o Foamburst o Micap Companies Covered • Actavis • Angelini • Applied Pharma Research • Ardana Biosciences • Auxillium Pharma  • Barr • Biodelivery Sciences • Blue fish • Cynapsus Pharma • Ethypharm • Galena • Galenica • Generex • Grunenthal • Indivior • Insys • Insys Therapeutics • IntelGenx  • Intellidrug • LTS Lohmann  • Meda Pharma • MedaPharm • Mist Pharma • Mystic Pharma • Neuraxpharm • Novadel • Novel Labs • Nycomed • Onexo • Oriform • Purdue • Rosedale Therapeutics • Roxane • Sandoz • Sanofi • Snoreeze • Tapemark  • Tesa Labtec Pharma • Teva Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters.


GAITHERSBURG, Maryland--(BUSINESS WIRE)--La nouvelle solution de soin des plaies Nexodyn® AOS Wound Care Solution, autorisée à la vente par la FDA, commence à être disponible aux Etats-Unis, promue et commercialisée par la société pharmaceutique italienne de premier plan Angelini, dans le cadre d'un partenariat exclusif établi avec la société suisse APR Applied Pharma Research, propriétaire et développeur de la technologie brevetée exclusive TEHCLO®, pour la production de solutions acides très


GAITHERSBURG, Md.--(BUSINESS WIRE)--Die von der FDA zum Verkauf zugelassene neue Wundversorgungslösung Nexodyn® AOS ist nun in den USA erhältlich. Sie wird vom führenden italienischen Pharmazieunternehmen Angelini gefördert und vermarktet. Grundlage ist eine exklusive Partnerschaft mit dem Schweizer Unternehmen APR Applied Pharma Research, dem Eigentümer und Entwickler der proprietären patentierten Technologie TEHCLO® zur Herstellung saurer, stark oxidierender Lösungen. Dank der Formulierung hi


GAITHERSBURG, Md.--(BUSINESS WIRE)--The new Nexodyn® AOS Wound Care Solution, cleared for sale by the FDA, is now starting to be available in the USA, promoted and commercialized by the leading Italian pharmaceutical company Angelini, as a result of an exclusive partnership with the Swiss Company APR Applied Pharma Research, the owner and developer of the proprietary, patented technology TEHCLO®, for the production of acidic super-oxidizing solutions. Thanks to its formulation, Nexodyn® helps c


GAITHERSBURG, Md.--(BUSINESS WIRE)--La nuova soluzione Nexodyn® AOS Wound Care, con autorizzazione alla vendita da parte della FDA, è ora disponibile negli Stati Uniti grazie all'attività di promozione e commercializzazione della casa farmaceutica italiana Angelini leader del settore, tramite una partnership esclusiva con la azienda svizzera APR Applied Pharma Research, che detiene e sviluppa la tecnologia proprietaria brevettata TEHCLO® per la produzione di soluzioni acide superossidanti. Graz


GAITHERSBURG, Md.--(BUSINESS WIRE)--La nueva solución Nexodyn® AOS Wound Care, autorizada para su venta por la FDA, ha comenzado a estar disponible en EE. UU., promocionada y comercializada por la empresa farmacéutica líder italiana,Angelini, como resultado de una alianza exclusiva con la empresa suiza, APR Applied Pharma Research, propietaria y desarrolladora de la tecnología propia y patentada TEHCLO®, para la producción de soluciones de soluciones ácidas superoxidantes. Gracias a su formulac


News Article | December 12, 2016
Site: www.businesswire.com

BALERNA, Switzerland--(BUSINESS WIRE)--APR Applied Pharma Research s.a. - the Swiss independent developer of science driven patented healthcare products - and MONRONE FZC Healthcare (Monrone), the middle east Outsourcing Health and Beauty business, have recently announced they have entered a partnership agreement to promote, distribute and market the Halykoo pediatric healthcare product line in Qatar, Kuwait, United Arab Emirates, Saudi Arabia, Oman, Bahrain. Halykoo is a global umbrella brand of pediatric OTC products conceived and developed by the Switzerland based company. Halykoo innovative portfolio includes 12 different products spanning four major therapeutic areas such as skin care, cough & cold, eye, ear & mouth and nutraceutical. They all rely on formulations and delivery systems specifically tailored to match babies and children different needs throughout each stage of their growth. This partnership will allow Monrone to accomplish its transition towards becoming an established pharmaceutical company within the Middle East countries offering high quality, innovative and branded products dedicated to infants and children, such as Halykoo. “We believe our partnership with APR is an opportunity to successfully gain a sizable share of the competitive paediatric healthcare market which, in the middle east region is worth up to 120 million $. We believe Halykoo provides problem solution products offering parents a simple, safe and innovative range of goods to deal with their babies healthcare issues. – comments Mohamed Samir – Market access manager, MONRONE FZC - We have worked hard to be recognized as a highly dynamic yet very caring provider in the market of OTC products: the innovative products within the Halykoo line, are able to set a new pace in the pediatric healthcare market while providing added value to our partners in full compliance with our company’s commitment for the future.” The deal between APR and MONRONE comes after previous marketing of Halykoo in Italy, Ukraine and the former Yugoslavia area, and thanks to this agreement APR will we able to introduce its brand also in the pediatric care market of many country of the Middle East, further expanding its network distribution across the world and confirming the strong appeal and distinctive positioning of Halykoo on an international scale. Paolo Galfetti, CEO and Co-Founder of APR, explained: “Providing parents worldwide with products that meet the specific needs of their children over the first six years of their lives, Halykoo line offers the unique opportunity to face the high consumer turnover given by babies ageing out of the category. We are proud to welcome MONRONE in our growing global network partners and strongly believe it will be an important partner for us as it holds the experience, the geographic reach and distribution infrastructure to best market and deliver Halykoo product range.” he added. Halykoo is a new global brand in the pediatric OTC market, conceived and developed by APR starting from an unmet demand driven insight, which aims to transform the moments of child healthcare in a time of relation (between mother and kid) peaceful, simple and safe in order to get parents’ confidence and smiling babies. Halykoo is the first and only OTC pediatric healthcare brand that matches formulations specifically focused on each of the unique ages and stages of children’s growth, since birth, with smart and innovative formulations and delivery systems intended to simplify their use for parents and reduce the hassle for babies. Halykoo products are the perfect combination of Swiss, high-quality research combined with an extensive understanding of child and caregivers needs: as a result, each Halykoo product provides the right formula – from accurate selection of the ingredients (including natural organic certified components), to careful dosing of the ingredients and full compliance with the strictest safety standards – and the right delivery system for the right age. For more info about Halykoo, please visit: www.halykoo.com Founded in 2012, the vision of MONRONE Healthcare. MONRONE is to become a ”widely respected regional & international Healthcare company” by advancing its mission of “persisting in Nutraceutical innovation for the benefit of human beings.” It focuses on constant improving, creating products through partnership with world class R&D laboratories that match the ever-changing lifestyles and needs of people and families everywhere. To date, over 44 of the company's products have been commercializing across the Middle-east, and over 600,000 patient leveraging these products, Monrone recognized as the most highly dynamics provider of over-the-counter products in Middle-east yet nimble enough to give detailed attention to each and every one of their products .To learn more about MONRONE, please visit us http://www.monrone.org APR is an independent Swiss company, specialized in the development of science-driven, patent-protected healthcare products. The Company identifies, develops and licenses science- driven, value-added products designed to address patient or consumer needs in selected therapeutic areas on a global basis. Specifically, APR is currently focused on 2 (two) major areas: (i) internally developed and financed (alone or with our co-development partners) proprietary, value-added products to be licensed to healthcare companies for their commercialization, and (ii) support to third-party projects, by offering value-added, R&D services under contract and fee for service arrangements. APR has a balanced pipeline of revenue-generating branded products marketed in all major markets, combined with a compelling pipeline of products at different development stages. APR has entered into licensing and partnership agreements with pharmaceutical companies in over 70 countries, with international sales on a worldwide basis. For more info, please visit: www.apr.ch.


GAITHERSBURG, Md.--(BUSINESS WIRE)--De nieuwe Nexodyn® AOS Wound Care Solution, goedgekeurd voor verkoop door de FDA, begint nu beschikbaar te worden in de VS. Het product wordt gepromoot en in de handel gebracht door het toonaangevende Italiaanse farmaceutische bedrijf Angelini, als gevolg van een exclusief samenwerkingsverband met de Zwitserse onderneming APR Applied Pharma Research, de eigenaar en ontwikkelaar van de eigen gepatenteerde technologie TEHCLO®, voor de productie van zure super-o


News Article | November 21, 2016
Site: www.newsmaker.com.au

According to Stratistics MRC, the Global Paper Diagnostics market is accounted for $4.0 billion in 2015 and is expected to reach $8.35 billion by 2022 growing at a CAGR of 11.08%. Rising prevalence of infectious diseases, rising ageing population with disorders and increasing cancer cases are some of the factors driving the market. Access the complete report at: http://www.strategymrc.com/report/paper-diagnostics-market Lateral flow assays segment accounted for the largest share and Dipsticks is expected to witness the highest share during the forecast period. The favourable growth is attributed to its high adoption in urine analysis in hospitals and clinical laboratories. Asia Pacific is expected to witness the highest CAGR during the forecast period owing to growing acceptance of home healthcare and growth in population. Some of the key players in global paper diagnostics market include BiognostiX, C.V, Navigate Genetic Science, GVS Filter Technology, Bio-Rad Laboratories, Micro Essential Laboratory, Alere Inc., Kenosha, Navigene Genetic Science Pvt Ltd., Diagnostics For All, GVS Filter Technology Inc. and Siemens Healthcare. Access the complete report at: http://www.strategymrc.com/report/paper-diagnostics-market Applications Covered: • Environmental Monitoring • Food Quality Testing • Clinical Diagnostics o Liver Disorders o Infectious Diseases o Cancer o Others Products Covered: • Lateral Flow Assays • Dipsticks End Users Covered: • Biotech-Pharma Research • Hospitals • Home Healthcare • Others Device Types Covered: • Monitoring Devices • Diagnostics Devices Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK  o Spain      o Rest of Europe  • Asia Pacific o Japan        o China        o India        o Australia        o New Zealand       o Rest of Asia Pacific       • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements

Loading Pharma Research collaborators
Loading Pharma Research collaborators